Clinical Trial Update: Safety & Efficacy of BCT197A2201 in COPD Patients Presenting With an Exacerbation [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating safety and efficacy of BCT197A2201 in COPD patients with exacerbation has been completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• BCT197A2201

Snippet

Sponsor: Mereo BioPharma | Conditions: Chronic Obstructive Pulmonary Disease | Phase 2 | Status: COMPLETED | Results posted: 2023-03-21